Geode Capital Management LLC Has $1.27 Million Stock Position in Fractyl Health, Inc. (NASDAQ:GUTS)

Geode Capital Management LLC raised its position in shares of Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) by 166.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 501,476 shares of the company's stock after purchasing an additional 313,335 shares during the period. Geode Capital Management LLC owned 1.04% of Fractyl Health worth $1,269,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. State Street Corp lifted its position in Fractyl Health by 129.4% in the third quarter. State Street Corp now owns 113,415 shares of the company's stock worth $287,000 after purchasing an additional 63,968 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Fractyl Health by 4.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company's stock valued at $2,646,000 after purchasing an additional 49,289 shares during the period. Barclays PLC increased its stake in shares of Fractyl Health by 1,754.7% in the 3rd quarter. Barclays PLC now owns 47,796 shares of the company's stock valued at $121,000 after acquiring an additional 45,219 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company's stock worth $204,000 after purchasing an additional 29,262 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Fractyl Health during the 3rd quarter worth approximately $51,000.

Fractyl Health Stock Down 2.6 %

Shares of GUTS stock traded down $0.05 during trading hours on Friday, hitting $1.85. 249,741 shares of the company were exchanged, compared to its average volume of 260,707. Fractyl Health, Inc. has a 52 week low of $1.74 and a 52 week high of $14.50. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The business has a 50 day moving average of $2.17 and a two-hundred day moving average of $2.80. The company has a market capitalization of $88.98 million and a PE ratio of -0.15.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.02. The firm had revenue of $0.01 million during the quarter. Analysts anticipate that Fractyl Health, Inc. will post -1.66 earnings per share for the current fiscal year.

Insider Activity

In other Fractyl Health news, insider Jay David Caplan sold 64,197 shares of the business's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $158,566.59. Following the completion of the sale, the insider now owns 153,544 shares of the company's stock, valued at $379,253.68. The trade was a 29.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Harith Rajagopalan sold 96,517 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $2.47, for a total value of $238,396.99. Following the sale, the chief executive officer now directly owns 491,329 shares in the company, valued at $1,213,582.63. This represents a 16.42 % decrease in their position. The disclosure for this sale can be found here.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.